Sutro Biopharma STRO 深 沪
已收盘 08-21 16:00:00 美东时间
21.04
-0.120
-0.57%
华盛通- 最 高21.86
- 今 开21.39
- 成交量 19.47万股
- 最 低 20.835
- 昨 收 21.16
- 总市值 3.49亿
- 52周最高 43.85
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 7.211
- 委 比 -50.12%
- 总股本 1658.12万
- 历史最高 283.00
- 量 比 0.60
- 振 幅 4.84%
- 历史最低 5.231
- 每 手 1
- 风险率 9.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target
Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $60 price target.
08-13 20:54
Why is Sutro Biopharma Stock Falling On Wednesday?
Sutro Biopharma, Inc. (NASDAQ:STRO) shares are trading lower on Wednesday as the company faces challenges following its recent update on the STRO-004 Phase 1 study. The STRIVE-01 study is evaluating STRO-004 in heavily pretreated patients with advanced solid tumors. What’s Driving Sutro Biopharma (S...
08-13 02:04
Sutro Biopharma shares are trading lower after the company reported worse-than-expected Q2 financial results.
Sutro Biopharma shares are trading lower after the company reported worse-than-expected Q2 financial results.
08-12 22:19
Sutro Biopharma Q2 Results Highlight Advancing ADC Pipeline
An announcement from Sutro Biopharma ( ($STRO) ) is now available. On August 12...
08-12 19:48
Sutro Biopharma Q2 EPS $(2.33) Misses $(2.19) Estimate, Sales $9.839M Miss $13.048M Estimate
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.33) per share which missed the analyst consensus estimate of $(2.19) by 6.39 percent. This is a 66.43 percent decrease over losses of $(1.40) per share from the same period last year. The company reported quarterly sales of $9.839 millio...
08-12 19:02
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
Sutro Biopharma reported positive early clinical data for its STRO-004 ADC, showing favorable tolerability and early responses in heavily pretreated patients with advanced solid tumors. The company also announced strong financials with $164.3 million in cash, supporting operations into 2028. STRO-006, a next-generation ADC targeting ITGB6, is set to enter the clinic in Q3 2026, while the first wholly-owned dual-payload ADC, STRO-227, is on track ...
08-12 11:00
Vaxcyte to Participate in Upcoming Investor Conferences
Vaxcyte, Inc. announced that its management will participate in one-on-one meetings at the Leerink Partners Therapeutics Forum on July 15, 2026, and the BTIG Virtual Biotechnology Conference on July 28, 2026. The company, focused on developing high-fidelity vaccines, is advancing several candidates, including VAX-31 and VAX-24 for pneumococcal disease prevention, VAX-A1 for Group A Strep, and VAX-GI for Shigella. Vaxcyte utilizes its XpressCF pla...
07-08 20:05
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Aura Biosciences appoints Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. Bender, a biotech leader with experience in advancing therapies and commercialization, joins as the company prepares for potential regulatory approval of bel-sar for early choroidal melanoma. Aura aims to develop precision therapies preserving organ function, with bel-sar in late-stage development. Bender previously led Day One Biopharmaceuticals through its $2.5 b...
07-08 11:01
